Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis
about
Update in Cystic Fibrosis 2014Animal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and DivergencesNew and emerging targeted therapies for cystic fibrosisAdvancing clinical development pathways for new CFTR modulators in cystic fibrosisTargeted therapies to improve CFTR function in cystic fibrosisEarly pulmonary inflammation and lung damage in children with cystic fibrosisNeutrophil plasticity enables the development of pathological microenvironments: implications for cystic fibrosis airway diseaseCFTR Modulators: Shedding Light on Precision Medicine for Cystic FibrosisCurrent and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its SymptomsPaediatrics: messages from MunichImpact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation.Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.CFTR Modulators for the Treatment of Cystic Fibrosis.Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.A call for accurate pharmacogenetic labeling: telling it like it isPharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammationPharmGKB summary: very important pharmacogene information for CFTRPseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor.Ivacaftor Therapy in CF Patients: Single Center Experience.Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time.The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy.Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trialLumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.Acute administration of ivacaftor to people with cystic fibrosis and a G551D-CFTR mutation reveals smooth muscle abnormalitiesCombination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy.Pilot evaluation of ivacaftor for chronic bronchitis.Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis.In vivo imaging of airway cilia and mucus clearance with micro-optical coherence tomography.Antiinflammatory effects of bromodomain and extraterminal domain inhibition in cystic fibrosis lung inflammationInterleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.Therapeutic Approaches to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis.Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic FibrosisGrowth in Prepubertal Children With Cystic Fibrosis Treated With IvacaftorIvacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutationNovel outcome measures for clinical trials in cystic fibrosisNew and Emerging Treatments for Cystic Fibrosis.Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
P2860
Q22306307-BF855404-ED69-4135-8E20-DD6485F49EFEQ26747210-0538515F-6207-4EAD-B173-42EA25992725Q26749278-1634B078-8296-44F4-BF0A-38EFEF3B4C0AQ26768266-CA946C7E-895D-4924-BB60-B1F50CCA3A4AQ26781441-CCA7F2B3-D633-41E4-8020-6AC1AD0806DFQ27027040-BFD81FBD-7889-433F-96C8-0D8D0BCC877AQ28071357-C871B1C3-D858-4E54-BB71-78C77813EE41Q28073996-CC740759-7BE3-4203-9301-FEC7A0C0D852Q28077411-0D874A2A-B540-4401-AF38-3ED08A6FDDC2Q28596759-8A85B29A-4EED-4F57-BFC0-32E63E20D858Q33551857-3F682585-1F1F-4446-8DA2-2E550AFC6C89Q33865292-6B4D8447-1236-47BA-AF12-AA0F083F3D5BQ33916434-DD533663-443D-47F6-9A22-F71F600683EEQ33920366-6B0521DC-FFD8-49DB-B70B-EE7CA43FA680Q34496122-33E27D2C-26AF-43E4-A74A-D37B655E3FC5Q34602508-1825CB11-CA8C-41F4-A5BA-21894BC2FA9FQ35073075-C7442A1A-DD4A-4947-910E-98F3F7775E35Q35108743-D22F7660-516C-4225-B06D-D8C57E71113DQ35127240-60A21A15-C5CD-4A75-8E28-D05100834374Q35326173-D2EC37BA-F10E-4272-AB08-0EC3D791E428Q36054346-679DDB83-85F3-4D5A-9AD0-FF4A91FF3473Q36112663-17F2708B-FFE8-46AB-851D-7B2D5C2E7A8FQ36215326-F8B57399-6144-489E-89FD-CF83E121AAE1Q36268539-9D0537C4-BDDD-4865-9E68-5ECD5A8BD2A1Q36433196-C3577D10-B872-45E9-9B74-0EBC5AC79EA2Q36609344-CB4DDC8D-C1C0-4EF5-B8BD-88EB04FB6863Q36865792-0FE2C712-CD30-4095-94B0-D13B8DA653CEQ36976621-C59610F8-7840-4591-B150-DA9C9DE7FC60Q37028545-B46AF14F-6D54-402D-B22C-802059032920Q37065065-7A8A9FB3-FB07-446E-A33A-BAC0C643DC83Q37103151-6761506B-38E3-4DD1-9D57-F27494BB8ABEQ37161413-F97C24EA-FBEE-4FCD-9F42-35384BAAB5D8Q37199853-B6453328-FE46-4367-9BF4-1FD17CA5238AQ37241561-479090D4-8C8C-48BC-A63D-81FC3226F3A7Q37241563-DCD0472A-D359-430A-B90A-ED25080AB97EQ37602780-76E24CAE-CBC0-40DB-A2CC-41F9B65F00B6Q37605093-70DD3872-CC80-4C8A-8DFA-EE9A64502631Q38340406-DCFFB49E-4C18-482D-9A8A-F7408FDF7D84Q38532426-EB28A054-C404-4BCE-94D6-EB76B6CDA59AQ38533943-4AAF96E5-196A-45C9-BFBF-1A3C0BEB4C75
P2860
Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis
@ast
Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis
@en
Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis
@nl
type
label
Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis
@ast
Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis
@en
Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis
@nl
prefLabel
Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis
@ast
Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis
@en
Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis
@nl
P2093
P2860
P1476
Clinical mechanism of the cyst ...... G551D-mediated cystic fibrosis
@en
P2093
Bonnie W Ramsey
Daniel Gelfond
Drucy Borowitz
Elizabeth Joseloff
GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network
Jill M Van Dalfsen
Nicole Mayer-Hamblett
Scott D Sagel
Scott H Donaldson
Sonya L Heltshe
P2860
P304
P356
10.1164/RCCM.201404-0703OC
P407
P577
2014-07-01T00:00:00Z